Argenx
Clinical trials sponsored by Argenx, explained in plain language.
Biopharmaceutical company developing antibody therapies for autoimmune diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Thyroid eye disease drug trial halted early – no safety concerns
Disease control TerminatedThis study tested a drug called efgartigimod for people with active, moderate-to-severe thyroid eye disease, a condition that causes bulging eyes and vision problems. About 102 adults took part, receiving either the drug or a placebo. The trial was stopped early because early res…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Thyroid eye disease drug trial halted after early results disappoint
Disease control TerminatedThis study tested a drug called efgartigimod for people with active, moderate-to-severe thyroid eye disease, a condition that causes bulging eyes and vision problems. About 105 adults were randomly assigned to receive either the drug or a placebo as a shot under the skin. The tri…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug shows promise for blistering skin disease in extended trial
Disease control TerminatedThis study looks at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who finished the main study can continue treatment for up to 48 weeks, with the option to pause and…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental drug for Post-COVID POTS study halted early
Disease control TerminatedThis study looked at the long-term safety of efgartigimod in adults with post-COVID postural orthostatic tachycardia syndrome (POTS), a condition causing rapid heart rate and dizziness upon standing. The trial was an open-label extension for people who completed a previous study.…
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC